Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Change in Acquisitions & Divestments (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $51.5 million as the latest value for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 19.8% year-over-year to $51.5 million; the TTM value through Dec 2025 reached $135.0 million, down 21.43%, while the annual FY2025 figure was $135.0 million, 21.43% down from the prior year.
  • Change in Acquisitions & Divestments hit $51.5 million in Q4 2025 for Kezar Life Sciences, up from $30.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $85.2 million in Q4 2022 and bottomed at $13.8 million in Q1 2025.
  • Average Change in Acquisitions & Divestments over 5 years is $46.8 million, with a median of $43.9 million recorded in 2021.
  • Year-over-year, Change in Acquisitions & Divestments skyrocketed 358.26% in 2023 and then tumbled 63.58% in 2025.
  • Kezar Life Sciences' Change in Acquisitions & Divestments stood at $31.0 million in 2021, then surged by 175.0% to $85.2 million in 2022, then dropped by 8.8% to $77.8 million in 2023, then crashed by 44.71% to $43.0 million in 2024, then grew by 19.8% to $51.5 million in 2025.
  • According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $51.5 million, $30.0 million, and $39.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.